

Clinical trials of sirolimus biodegradable polymer

TrialResults-center www.trialresultscenter.org

1 stable angina

Trial	Treatments	Patients	Trials design and methods
sirolimus biodegradable polymer vs sirolimus eluting stent			
ISAR-TEST-4 (biodegradable polymer) , 2009 [NCT00598676].] n=1299/1304 follow-up: 12 mo	biodegradable polymer rapamycin-eluting stent versus permanent polymer-based rapamycin-eluting or everolimus-eluting	patients with stable coronary disease or acute coronary syndromes with de novo native-vessel stent implantation	Parallel groups open Germany

More details and results :

- myocardial revascularization for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q25>

References

ISAR-TEST-4 (biodegradable polymer), 2009:

Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schmig A, Mehilli J Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009 Aug 30;: [[19720642](#)]

2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
sirolimus biodegradable polymer vs sirolimus eluting stent			
ISAR TEST 3 (BP) , 2009 n=202/202 follow-up: 12 months	biodegradable-polymer 0.4% rapamycin stent (180 mg rapamycin/cm2) versus permanent-polymer rapamycin-eluting stent (Cypher) (140 mg rapamycin/cm2)	Patients with de novo coronary lesions in native vessels	Parallel groups open Germany

continued...

Trial	Treatments	Patients	Trials design and methods
ISAR-TEST-4 (biodegradable polymer) , 2009 [NCT00598676].] n=1299/1304 follow-up: 12 mo	biodegradable polymer rapamycin-eluting stent versus permanent polymer-based rapamycin-eluting or everolimus-eluting	patients with stable coronary disease or acute coronary syndromes with de novo native-vessel stent implantation	Parallel groups open Germany

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at <http://www.trialresultscenter.org/go-Q26>
- Drug eluting stent for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q206>
- Drug eluting stent for coronary artery disease in unparticular patients at <http://www.trialresultscenter.org/go-Q215>

References

ISAR TEST 3 (BP), 2009:

Mehilli J, Byrne RA, Wiecek A, Iijima R, Schulz S, Bruskin O, Pache J, Wessely R, Schmig A, Kastrati A Eur Heart J 2008 Aug;29:1975-82 [[18550554](#)]
[10.1093/eurheartj/ehn253](#)

Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, Schulz S, Mehilli J Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009;95:1489-94 [[19592388](#)]

ISAR-TEST-4 (biodegradable polymer), 2009:

Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schmig A, Mehilli J Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009 Aug 30;: [[19720642](#)]